SGLT2i Use Linked to Lower Risk of Nephrolithiasis in Patients With Type 2 Diabetes
Compared to glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, Use of sodium-glucose cotransporter 2 inhibitors was linked to a decreased risk of nephrolithiasis in patients with type 2 diabetes.
Julie Paik Us Centers For Disease Centers For Disease Harvard Medical School Women Hospital Harvard Medical School Julie Paik Disease Control
Source: hcplive.com